Michael Amylon

Publication Details

  • Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with P16/P15 deletions LEUKEMIA RESEARCH Diccianni, M. B., Batova, A., Yu, J., Vu, T., Pullen, J., Amylon, M., Pollock, B. H., Yu, A. L. 1997; 21 (6): 549-558


    p16 Alterations were detected in > 60% of 103 primary T-ALL samples. In paired diagnosis-relapse patient samples, 80% of the relapse samples with p16 deletion were deleted at diagnosis. When p16 was homozygously deleted, p15 gene alterations were found in 72% of the diagnosis T-ALL patient samples, increasing significantly to 100% at relapse. Alterations of p18 were not detected. No clinical significance of p15/p16 gene deletion in diagnosis T-ALL was found with respect to white blood cell (WBC) count, incidence of mediastinal mass, rate of relapse, duration of first remission or event-free survival. In relapse T-ALL, however, patients with p16 deletion experienced a significantly shorter duration of post-relapse survival, demonstrating that p16 deletion is clinically significant in T-ALL.

    View details for Web of Science ID A1997XR42800008

    View details for PubMedID 9279366

Stanford Medicine Resources:

Footer Links: